News

bit.bio adds $100M+ to its coffers and some impressive names to its board of directors.

Dr Davide Danovi talks to The Academy of Medical Sciences as a FLIER participant in cross-sector leadership programme.

This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.

The book celebrates leadership and innovation and covers bit.bio's ambition to engineer the future of medicine. 

Short film showcases innovative cell reprogramming technology at event.

Founder and CEO Mark Kotter talks to Eva (The Naked Scientist podcast) about all things cell reprogramming.

Find out why animals are not always ideal when studying potential treatments for diseases like Alzheimer's.

This piece covers what's different about our cell coding approach.